SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc. have published an international patent for a novel ibogaine-based therapy aimed at enhancing safety and efficacy in treating mental health and addiction issues. The collaboration focuses on combining psychedelic molecules with N-acylethanolamines, aiming to further the development of innovative treatments. SciSparc’s drug development programs are centered on cannabinoid pharmaceuticals, targeting a range of central nervous system disorders and rare diseases.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
